Pre‑clinical animal studies suggest that BPC‑157 (a synthetic peptide fragment of body‑protective protein) may promote tissue healing, angiogenesis, and gastrointestinal protection. Human clinical data are limited to small case series and anecdotal reports.
Potential adverse effects are not well characterised. Reported concerns include local irritation, hypotension, and unknown long‑term effects. Because human studies are scarce, safety cannot be reliably assessed.
Regulatory agencies such as the FDA have not approved BPC‑157 for any medical indication. It is typically classified as a research chemical, and distribution for human use may be illegal in many jurisdictions.
All information is provided for educational purposes only.